Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-20T21:22:14.784Z Has data issue: false hasContentIssue false

18 - Psychosis Secondary to Inflammatory and Demyelinating Disease

from Part V - Central Nervous System Disorders

Published online by Cambridge University Press:  06 January 2010

Katherine H. Taber
Affiliation:
VISN 6 MIRECC, Hefner VAMC, WFGSM, BCM, Salisbury, North Carolina
Robin A. Hurley
Affiliation:
VISN 6 MIRECC, Hefner VAMC, WFGSM, BCM, Salisbury, North Carolina
Daryl Fujii
Affiliation:
University of Hawaii, Manoa
Iqbal Ahmed
Affiliation:
University of Hawaii, Manoa
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Spectrum of Psychotic Disorders
Neurobiology, Etiology and Pathogenesis
, pp. 337 - 366
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abbott, N., Mendonça, L., & Dolman, D. (2003). The blood–brain barrier in systemic lupus erythematosus. Lupus, 12, 908–15.CrossRefGoogle Scholar
ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999). The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism, 42(4), 599–609.
Adorini, L. (2004). Immunotherapeutic approaches in multiple sclerosis. Journal of Neurological Sciences, 223, 13–24.CrossRefGoogle Scholar
Ainiala, H., Loukkola, M. A., Peltola, J., Korpela, M., & Hietaharju, A. (2001). The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology, 57, 496–500.CrossRefGoogle Scholar
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., et al. (2003). Development of autoantibodies before clinical onset of systemic lupus erythematosus. New England Journal of Medicine, 349(16), 1526–33.Google Scholar
Asghar-Ali, A., Taber, K. H., Hurley, R. A., & Hayman, L. A. (2004). Pure neuropsychiatric presentation of multiple sclerosis. American Journal of Psychiatry, 161(2), 226–31.CrossRefGoogle Scholar
Bakshi, R., Hutton, G. J., Miller, J. R., & Radue, E.-W. (2004). The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology, 63(11 Suppl. 5), S3–11.CrossRefGoogle Scholar
Barnett, M. H. & Prineas, J. W. (2004). Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Annals of Neurology, 55, 458–68.CrossRefGoogle Scholar
Baumann, N., Turpin, J. C., Lefevre, M., & Colsch, B. (2002). Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: Genotype/phenotype relationships?. Journal of Physiology - Paris, 96, 301–6.CrossRefGoogle Scholar
Benes, F. M. (2000). Emerging principles of altered neuronal circuitry in schizophrenia. Brain Research Reviews, 31, 251–69.CrossRefGoogle Scholar
Berger, J., Loschl, B., Bernheimer, H., et al. (1997). Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. American Journal of Medical Genetics, 69(3), 335–40.3.0.CO;2-R>CrossRefGoogle Scholar
Black, D. N., Taber, K. H., & Hurley, R. A. (2003). Metachromatic leukodystrophy: A model for the study of psychosis. Journal of Neuropsychiatry and Clinical Neurosciences, 15(3), 289–93.CrossRefGoogle Scholar
Bodani, M. & Kopelman, M. D. (2003). A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus. Lupus, 12, 947–9.CrossRefGoogle Scholar
Bostantjopoulou, S., Katsarou, Z., Michelakaki, H., & Kazis, A. (2000). Seizures as a presenting feature of late onset metachromatic leukodystrophy. Acta Neurologica Scandinavica, 102, 192–5.Google Scholar
Brey, R. L. & Petri, M. A. (2003). Neuropsychiatric systemic lupus erythematosus. Miles to go before we sleep. Neurology, 61, 9–10.Google Scholar
Brey, R. L., Holliday, S. L., Saklad, A. R., et al. (2002). Neuropsychiatric syndromes in lupus. Prevalence using standardized definitions. Neurology, 58, 1214–20.CrossRefGoogle Scholar
Brown, E. S. & Chandler, P. A. (2001). Mood and cognitive changes during systemic corticosteroid therapy. Primary Care Companion to the Journal of Clinical Psychiatry, 3(1), 17–21.Google Scholar
Carson, H. J. & Searle-White, D. J. (1996). Occult multiple sclerosis presenting with psychosis. Canadian Journal of Psychiatry, 41(7), 486–7.CrossRefGoogle Scholar
Chau, S. Y. & Mok, C. C. (2003). Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology, 61(1), 104–7.CrossRefGoogle Scholar
Chen, J. J. H., Yen, R. F., Kao, A., Lin, C. C., & Lee, C. C. (2002). Abnormal regional cerebral blood flow found by technetium-99m ethyl cysteinate dimer brain single photon emission computed tomography in systemic lupus erythematosus patients with normal brain MRI findings. Clinical Rheumatology, 21(6), 516–19.CrossRefGoogle Scholar
Chong, S. A. & Ko, S. M. (1997). Clozapine treatment of psychosis associated with multiple sclerosis. Canadian Journal of Psychiatry, 42(1), 90–1.Google Scholar
Clarke, T., Wadhwa, U., & Leroi, I. (1998). Psychotic depression: An atypical initial presentation of multiple sclerosis. Psychosomatics, 39(1), 72–5.CrossRefGoogle Scholar
Compston, A. (1999). The genetic epidemiology of multiple sclerosis. Philosophical Transactions of the Royal Society of London Biological Sciences, 354, 1623–34.CrossRefGoogle Scholar
Conti, F., Alessandri, C., Bompane, D., et al. (2004). Autoantobody profile is systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Research and Therapy, 6, R366–72.CrossRefGoogle Scholar
Costallat, L., Bertolo, M., & Appenzeller, S. (2001). The American College of Rheumatology (ACR) nomenclature and case definitions for neuropsychiatric lupus syndromes. Analysis of 527 patients. Lupus, 10(Suppl.), S32.Google Scholar
Dall'Era, M. & Davis, J. C. (2003). Systemic lupus erythematosus. How to manage, when to refer. Postgraduate Medicine, 114(5), 31–7.CrossRefGoogle Scholar
Davids, E., Hartwig, U., & Gastpar, M. (2004). Antipsychotic treatment of psychosis associated with multiple sclerosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 743–4.CrossRefGoogle Scholar
Groot, C. J. A., Bergers, E., Kamphorst, W., et al. (2001). Post-mortem MRI-guided sampling of multiple sclerosis brain lesions. Increased yield of active demyelinating and (p)reactive lesions. Brain, 124, 1635–45.CrossRefGoogle Scholar
DeGiorgio, L. A., Konstantinov, K. N., Lee, S. C., et al. (2001). A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine, 7(11), 1189–93.CrossRefGoogle Scholar
Diaz-Olavarrieta, C., Cummings, J. L., Velazquez, J., & al Cadena, C. G. (1999). Neuropsychiatric manifestations of multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 11(1), 51–7.Google Scholar
Dubey, P., Fatemi, A., Barker, P. B., et al. (2005). Spectroscopic evidence of cerebral axonopathy in patients with “pure” adrenomyeloneuropathy. Neurology, 64(2), 304–10.CrossRefGoogle Scholar
Eichler, F. S., Barker, P. B., Cox, C., et al. (2002a). Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology, 58(6), 901–7.Google Scholar
Eichler, F. S., Itoh, R., Barker, P. B., et al. (2002b). Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: Initial experience. Radiology, 225(1), 245–52.Google Scholar
Engelbrecht, V., Scherer, A., Rassek, M., Witsack, H. J., & Modder, U. (2002). Diffusion-weighted MR imaging in the brain in children: Findings in the normal brain and in the brain with white matter diseases. Radiology, 222, 410–18.CrossRefGoogle Scholar
Feinstein, A. (2004). The neuropsychiatry of multiple sclerosis. Canadian Journal of Psychiatry, 49(3), 157–63.CrossRefGoogle Scholar
Feinstein, A. & Ron, M. (1998). A longitudinal study of psychosis due to a general medical (neurological) condition: Establishing predictive and construct validity. Journal of Neuropsychiatry and Clinical Neurosciences, 10(4), 448–52.CrossRefGoogle Scholar
Feinstein, A., Du Boulay, G., & Ron, M. A. (1992). Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. British Journal of Psychiatry, 161, 680–5.CrossRefGoogle Scholar
Felgenhauer, K. (1990). Psychiatric disorders in the encephalitic form of multiple sclerosis. Journal of Neurology, 237(1), 11–18.CrossRefGoogle Scholar
Filippi, M., Bozzali, M., Rovaris, M., et al. (2003). Evidence for widespread axonal damage at the earliest clinical stage in multiple sclerosis. Brain, 126, 433–7.CrossRefGoogle Scholar
Finelli, P. F. (1985). Metachromatic leukodystrophy manifesting as a schizophrenic disorder – Computed tomographic correlation. Annals of Neurology, 18(1), 94–5.CrossRefGoogle Scholar
Fluharty, A. L. (1990). The relationship of the metachromatic leukodystrophies to neuropsychiatric disorders. Molecular and Chemical Neuropathology, 13, 81–94.CrossRefGoogle Scholar
Fox, R. J. & Ransohoff, R. M. (2004). New directions in MS therapeutics: Vehicles of hope. Trends in Immunology, 25(12), 632–6.Google Scholar
Fukutani, Y., Noriki, Y., Sasaki, K., et al. (1999). Adult-type metachromatic leukodystrophy with a compound heterozygote mutation showing character change and dementia. Psychiatry and Clinical Neurosciences, 53(3), 425–8.CrossRefGoogle Scholar
Garside, S., Rosebush, P. I., Levinson, A. J., & Mazurek, M. F. (1999). Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. Journal of Clinical Psychiatry, 60(7), 460–8.Google Scholar
Ghezzi, A. (2004). Clinical characteristics of multiple sclerosis with early onset. Neurological Sciences, 25(Suppl. 4), S336–9.CrossRefGoogle Scholar
Gieselmann, V., Franken, S., Klein, D., et al. (2003). Metachromatic leukodystrophy: Consequences of sulphatide accumulation. Acta Paediatrica Supplementa, 92(443), 74–9.CrossRefGoogle Scholar
Goldblatt, F. & Isenberg, D. (2005). New therapies for systemic lupus erythematosus. Clinical and Experimental Immunology, 140(2), 205–12.CrossRefGoogle Scholar
Goodin, D. S. (2004). Disease modifying therapy in MS: A critical review of the literature. Part II: Assessing efficacy and dose-response. Journal of Neurology, 251(Suppl. 5), V/50–56.Google Scholar
Gothelf, D., Levite, R., & Gadoth, N. (2000). Bipolar affective disorder heralding cerebral demyelination in adreno-myelo-leukodystrophy. Brain and Development, 22(3), 184–7.CrossRefGoogle Scholar
Govoni, M., Castellino, G., Padovan, M., Borrelli, M., & Trotta, F. (2004). Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus, 13(3), 149–58.Google Scholar
Graham, J. W. & Jan, W. (2003). MRI and the brain in systemic lupus erythematosus. Lupus, 12(12), 891–6.Google Scholar
Handa, R., Sahota, P., Kumar, M., et al. (2003). In vivo proton magnetic resonance spectroscopy (MRS) and single photon emission computerized tomography (SPECT) in systemic lupus erythematosus (SLE). Magnetic Resonance Imaging, 21(9), 1033–7.CrossRefGoogle Scholar
He, J., Inglese, M., Li, B. S. Y., et al. (2005). Relapsing–remitting multiple sclerosis: Metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging. Initial experience. Radiology, 234(1), 211–17.CrossRefGoogle Scholar
Heilä, H., Turpeinen, P., & Erkinjuntti, T. (1995). Case study: Mania associated with multiple sclerosis. Journal of the American Academy of Child and Adolescent Psychiatry, 34(12), 1591–5.CrossRefGoogle Scholar
Hermosillo-Romo, D. & Brey, R. L. (2002). Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Practice and Research Clinical Rheumatology, 16(2), 229–44.CrossRefGoogle Scholar
Hernán, M. A., Olek, M. J., & Ascherio, A. (1999). Geographic variation of MS incidence in two prospective studies of US women. Neurology, 53(8), 1711–18.CrossRefGoogle Scholar
Herrera, B. M. & Ebers, G. C. (2003). Progress in deciphering the genetics of multiple sclerosis. Current Opinion in Neurology, 16, 253–8.CrossRefGoogle Scholar
Holve, S., Hu, D., & McCandless, S. E. (2001). Metachromatic leukodystrophy in the Navajo: Fallout of the American-Indian wars of the nineteenth century. American Journal of Medical Genetics, 101(3), 203–8.CrossRefGoogle Scholar
Honer, W. G., Hurwitz, T., Li, D. K. B., Palmer, M., & Paty, D. W. (1987). Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Archives of Neurology, 44, 187–90.CrossRefGoogle Scholar
Huang, W. S., Chiu, P. Y., Tsai, C. H., Kao, A., & Lee, C. C. (2002). Objective evidence of abnormal regional cerebral blood flow in patients with systemic lupus erythematosus on Tc-99m ECD brain SPECT. Rheumatology International, 22(5), 178–81.CrossRefGoogle Scholar
Hurley, R. A., Taber, K. H., Zhang, J., & Hayman, L. A. (1999). Neuropsychiatric presentation of multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 11(1), 5–7.CrossRefGoogle Scholar
Husebye, E. S., Sthoeger, Z. M., Dayan, M., et al. (2005). Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 64, 1210–3.CrossRefGoogle Scholar
Hyde, T. M., Ziegler, J. C., & Weinberger, D. R. (1992). Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Archives of Neurology, 49, 401–6.Google Scholar
Ito, R., Melhem, E. R., Mori, S., et al. (2001). Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology, 56(4), 544–7.CrossRefGoogle Scholar
Jennekens, F. & Kater, L. (2002a). The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: A literature investigation. Rheumatology, 41, 619–30.Google Scholar
Jennekens, F. & Kater, L. (2002b). The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: A literature investigation. Rheumatology, 41, 605–18.Google Scholar
Jiménez, S., Cervera, R., Font, J., & Ingelse, M. (2003). The epidemiology of systemic lupus erythematosus. Clinical Reviews in Allergy and Immunology, 25(1), 3–12.CrossRefGoogle Scholar
Johannsen, P., Ehlers, L., & Hansen, H. J. (2001). Dementia with impaired temporal glucose metabolism in late-onset metachromatic leukodystrophy. Dementia and Geriatric Cognitive Disorders, 12, 85–8.CrossRefGoogle Scholar
Jönsen, A., Bengtsson, A. A., Nived, O., Ryberg, B., & Sturfelt, G. (2002). Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology, 41, 1308–12.CrossRefGoogle Scholar
Karassa, F. B., Ioannidis, J. P. A., Boki, K. A., et al. (2000). Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. American Journal of Medicine, 109, 628–34.Google Scholar
Keegan, B. M. & Noseworthy, J. H. (2002). Multiple sclerosis. Annual Review of Medicine, 53, 285–302.Google Scholar
Khan, S., Haddad, P., Montague, L., & Summerton, C. (2000). Systemic lupus erythematosus presenting as mania. Acta Psychiatrica Scandinavica, 101, 406–8.CrossRefGoogle Scholar
Kikukawa, K., Toyama, H., Katayama, M., et al. (2000). Early and delayed Tc-99m ECD brain SPECT in SLE patients with CNS involvement. Annals of Nuclear Medicine, 14(1), 25–32.CrossRefGoogle Scholar
Kim, T. S., Kim, I. O., Kim, W. S., et al. (1997). MR of childhood metachromatic leukodystrophy. American Journal of Neuroradiology, 18(4), 733–8.Google Scholar
Kohn, H., Manowitz, P., Miller, M., & Kling, A. (1988). Neuropsychological deficits in obligatory heterozygotes for metachromatic leukodystrophy. Human Genetics, 79, 8–12.CrossRefGoogle Scholar
Kopala, L. C., Tan, S., Shea, C., et al. (2000). Adrenoleukodystrophy associated with psychosis. Schizophrenia Research, 45(3), 263–5.Google Scholar
Lai, N.-S. & Lan, J.-L. (2000). Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations. Lupus, 9(5), 353–7.CrossRefGoogle Scholar
Lejoyeux, M., Dubois, G., Turpin, J. C., & Lemperiere, T. (1989). Arylsulfatase A activity among psychotic-patients. Psychiatry Research, 30(1), 107–8.CrossRefGoogle Scholar
Leo, R. J. (1998). Behavioral changes and affective instability associated with adult-onset adrenoleukodystrophy. Psychosomatics, 39(2), 176–7.Google Scholar
Loes, D. J., Fatemi, A., Melhem, E. R., et al. (2003). Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology, 61(3), 369–74.CrossRefGoogle Scholar
López-Medrano, F., Cervera, R., Trejo, O., Font, J., & Ingelmo, M. (2002). Steroid induced psychosis in systemic lupus erythematosus: A possible role of serum albumin level. Annals of the Rheumatic Diseases, 61(6), 562–3.CrossRefGoogle Scholar
Lucchinetti, C., Brück, W., Parisi, J., et al. (2000). Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology, 47, 707–17.3.0.CO;2-Q>CrossRefGoogle Scholar
Luda, E. & Barisone, M. G. (2001). Adult-onset adrenoleukodystrophy: A clinical and neuropsychological study. Neurological Research, 22, 21–5.CrossRefGoogle Scholar
Lyoo, I. K., Seol, H. Y., Byun, H. S., & Renshaw, P. F. (1996). Unsuspected multiple sclerosis in patients with psychiatric disorders: A magnetic resonance imaging study. Journal of Neuropsychiatry and Clinical Neurosciences, 8(1), 54–9.Google Scholar
Mack, A. H., Fricchione, G., & Rogers, M. P. (2002). Neuropsychiatric systemic lupus erythematosus, age, and the neurodevelopmental model: Evidence in support of the Weinberger hypothesis. Comprehensive Psychiatry, 43(2), 135–41.CrossRefGoogle Scholar
Malur, C., Pasol, E., & Francis, A. (2001). ECT for prolonged catatonia. Journal of ECT, 17(1), 55–9.CrossRefGoogle Scholar
Manson, J. & Isenberg, D. (2003). The pathogenesis of systemic lupus erythematosus. Netherlands Journal of Medicine, 61(11), 343–6.Google Scholar
Maria, B. L., Deidrick, K. M., Moser, H., & Naidu, S. (2003). Leukodystrophies: Pathogenesis, diagnosis, strategies, therapies, and future research directions. Journal of Child Neurology, 18(9), 578–90.CrossRefGoogle Scholar
Mayr, W. T., Pittock, S. J., McClelland, R. L., et al. (2003). Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology, 61(10), 1373–7.Google Scholar
McKusick, V. A. (2003). Metachromatic leukodystrophy. Online Mendelian Inheritance in Manwww.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=250100.
Meier, D. S., Weiner, H. L., Khoury, S. J., & Guttman, C. R. G. (2004). Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. Journal of Neuroimaging, 14(3 Suppl.), 46–53S.CrossRefGoogle Scholar
Mendhekar, D. N., Mehta, R., & Puri, V. (2004). Successful steroid therapy in multiple sclerosis presented as acute psychosis. Journal of Association of Physicians of India, 52, 512–13.Google Scholar
Mikdashi, J. & Handwerger, B. (2004). Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the Maryland lupus cohort. Rheumatology, 43, 1555–60.CrossRefGoogle Scholar
Milstone, A. M., Meyers, K., & Elia, J. (2005). Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): A case report and review of the literature. Clinical Rheumatology.CrossRefGoogle Scholar
Modrego, J. & Ferrández, J. (2000). Familial multiple sclerosis with repetitive relapses of manic psychosis in two patients (mother and daughter). Behavioural Neurology, 12(4), 175–9.CrossRefGoogle Scholar
Mok, C. C., Lau, C. S., & Wong, R. W. S. (2003). Treatment of lupus psychosis with oral cyclophosphamide followed by azathiprine maintenance: An open-label study. American Journal of Medicine, 115(1), 59–62.CrossRefGoogle Scholar
Moser, H. W. (1997). Adrenoleukodystrophy: Phenotype, genetics, pathogenesis, and therapy. Brain, 120, 1485–508.CrossRefGoogle Scholar
Moser, H. W., Dubey, P., & Fatemi, A. (2004a). Progress in X-linked adrenoleukodystrophy. Current Opinion in Neurology, 17, 263–9.Google Scholar
Moser, H. W., Fatemi, A., Zackowski, K., et al. (2004b). Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochemical Research, 29(5), 1003–16.Google Scholar
Nath, S., Kelly, J., Reid, J., et al. (2002). SLEB3 in systemic lupus erythematosus (SLE) is strongly related to SLE families ascertained through neuropsychiatric manifestations. Human Genetics, 111, 54–8.Google Scholar
Neumann, H. (2003). Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Current Opinion in Neurology, 16, 267–73.CrossRefGoogle Scholar
Noonan, C. W., Kathman, S. J., & White, M. C. (2002). Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology, 58(1), 136–8.CrossRefGoogle Scholar
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. (2000). Multiple sclerosis. New England Journal of Medicine, 343(13), 938–52.CrossRefGoogle Scholar
Oguz, K. K., Anlar, B., Senbil, N., & Cila, A. (2004). Diffusion-weighted imaging findings in juvenile metachromatic leukodystrophy. Neuropediatrics, 35(5), 279–82.Google Scholar
Oku, K., Atsumi, T., Furukawa, S., et al. (2003). Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology, 42(6), 773–7.Google Scholar
Omdal, R. (2002). Some controversies of neuropsychiatric systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 31(4), 192–7.CrossRefGoogle Scholar
Owens, T. (2003). The enigma of multiple sclerosis: Inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Current Opinion in Neurology, 16, 259–65.CrossRefGoogle Scholar
Paintlia, A. S., Gilg, A. G., Khan, M., et al. (2003). Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: Implications for potential therapies. Neurobiology of Disease, 14(3), 425–39.CrossRefGoogle Scholar
Peters, C., Charnas, L. R., Tan, Y., et al. (2004). Cerebral X-linked adrenoleukodystrophy: The international hematopoietic cell transplantation experience from 1982 to 1999. Blood, 104(3), 881–8.CrossRefGoogle Scholar
Petri, M. (2002). Epidemiology of systemic lupus erythematosus. Best Practice and Research Clinical Rheumatology, 16(5), 847–58.CrossRefGoogle Scholar
Pitt, D., Nagelmeier, I. E., Wilson, H. C., & Raine, C. S. (2003). Glutamate uptake by oligodendrocytes. Implications for excitotoxicity in multiple sclerosis. Neurology, 61(8), 1113–20.Google Scholar
Propping, P., Friedl, W., Huschka, M., et al. (1986). The influence of low arylsulfatase-A activity on neuropsychiatric morbidity – a large-scale screening in patients. Human Genetics, 74(3), 244–8.CrossRefGoogle Scholar
Reichlin, M. (2003). Ribosomal P antibodies and CNS lupus. Lupus, 12(12), 916–18.CrossRefGoogle Scholar
Rosebush, P. I., Garside, S., Levinson, A. J., & Mazurek, M. F. (1999). The neuropsychiatry of adult-onset adrenoleukodystrophy. Journal of Neuropsychiatry and Clinical Neurosciences, 11(3), 315–27.CrossRefGoogle Scholar
Ruggieri, P. M., Iannetti, P., Polizzi, A., Pavone, L., & Grimaldi, L. M. E. (2004). Multiple sclerosis in children under 10 years of age. Neurological Sciences, 25(Suppl. 4), S326–35.CrossRefGoogle Scholar
Sabbadini, M. G., Manfredi, A. A., Bozzolo, E., et al. (1999). Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus, 8(11), 19.CrossRefGoogle Scholar
Salmon, E., Linden, M., Noordhout, A. M., et al. (1999). Early thalamic and cortical hypometabolism in adult-onset dementia due to metachromatic leukodystrophy. Acta Neurologica Belgica, 99(3), 185–8.Google Scholar
Sanna, G., Piga, M., Terryberry, J. W., et al. (2000). Central nervous system involvement in systemic lupus erythematosus: Cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus, 9(8), 573–83.CrossRefGoogle Scholar
Sanna, G., Bertolaccini, M. L., Cuadrado, M. J., et al. (2003a). Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. Journal of Rheumatology, 30, 985–92.Google Scholar
Sanna, G., Bertolaccini, M. L., & Mathieu, A. (2003b). Central nervous system lupus: A clinical approach to therapy. Lupus, 12(12), 935–42.Google Scholar
Sarchielli, P., Greco, L., Floridi, A., Floridi, A., & Gallai, V. (2003). Excitatory amino acids and multiple sclerosis. Evidence from cerebrospinal fluid. Archives of Neurology, 60(8), 1082–8.CrossRefGoogle Scholar
Schapiro, R. T. (2002). Pharmacologic options for the management of multiple sclerosis symptoms. Neurorehabilitation and Neural Repair, 16(3), 223–31.CrossRefGoogle Scholar
Schestag, F., Yaghootfam, A., Habetha, M., et al. (2002). The functional consequences of mis-sense mutations affecting an intra-molecular salt bridge in arylsulphatase A. Biochemical Journal, 367(Pt 2), 499–504.CrossRefGoogle Scholar
Schneider, J. F. L., Il'yasov, K. A., Boltshauser, E., Hennig, J., & Martin, E. (2003). Diffusion tensor imaging in cases of adrenoleukodystrophy: Preliminary experience as a marker of early demyelination?American Journal of Neuroradiology, 24(5), 819–24.Google Scholar
Sener, R. N. (2002). Metachromatic leukodystrophy: Diffusion MR imaging findings. American Journal of Neuroradiology, 23(8), 1424–6.Google Scholar
Sener, R. N. (2003). Diffusion MR imaging and proton MR spectroscopy. Acta Radiologica, 44(4), 440–3.Google Scholar
Shah, S. N. (1990). Arylsulfatase A (Asa) defect and psychiatric-illness – A review. Molecular and Chemical Neuropathology, 12(2), 121–9.CrossRefGoogle Scholar
Shimojima, Y., Matsuda, M., Gono, T., Ishii, W., & Ikeda, S.-I. (2005). Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clinical Rheumatology, 24, 469–75.CrossRefGoogle Scholar
Sibbitt, W. L. Jr., Brandt, J. R., Johnson, C. R., et al. (2002). The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. Journal of Rheumatology, 29, 1536–42.Google Scholar
Sirois, F. (2003). Steroid psychosis: A review. General Hospital Psychiatry, 25(1), 27–33.CrossRefGoogle Scholar
Sotgui, S., Pugliatti, M., Fois, M. L., et al. (2004). Genes, environment, and susceptibility to multiple sclerosis. Neurobiology of Disease, 17(2), 131–43.CrossRefGoogle Scholar
Tamagaki, C., Murata, A., Saito, A., & Kinoshita, T. (2000). Two siblings with adult-type metachromatic leukodystrophy: Correlation between. Seishin Shinkeigaku Zasshi, 102, 399–409.Google Scholar
Traynor, A. E., Barr, W. G., Rosa, R. M., et al. (2002). Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis and Rheumatism, 46(11), 2917–23.CrossRefGoogle Scholar
Tsao, B. P. (2003). The genetics of human systemic lupus erythematosus. Trends in Immunology, 24(11), 595–602.CrossRefGoogle Scholar
Turkel, S. B., Miller, J. H., & Reiff, A. (2001). Case series: Neuropsychiatric symptoms with pediatric systemic lupus erythematosus. Journal of the American Academy of Child and Adolescent Psychiatry, 40(4), 482–5.CrossRefGoogle Scholar
Voorn, J. P., Pouwels, P. J. W., Kamphorst, W., et al. (2005). Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. American Journal of Neuroradiology, 26(3), 442–6.Google Scholar
Vrenken, H., Barkhof, F., Uitdehaag, B. M. J., et al. (2005). MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magnetic Resonance in Medicine, 53(2), 256–66.CrossRefGoogle Scholar
Wada, K., Yamada, N., Sato, T., et al. (2001). Corticosteroid-induced psychotic and mood disorders. Diagnosis defined by DSM-IV and clinical pictures. Psychosomatics, 42(6), 461–6.Google Scholar
Werner, P., Pitt, D., & Raine, C. S. (2001). Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Annals of Neurology, 50, 169–80.CrossRefGoogle Scholar
Williams, R. C. Jr., Sugiura, K., & Tan, E. M. (2004). Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism, 50(4), 1239–47.CrossRefGoogle Scholar
Young, C. R., Weiss, E. L., Bowers, M. B. Jr. & Mazure, C. M. (1997). The differential diagnosis of multiple sclerosis and bipolar disorder. Journal of Clinical Psychiatry, 58(3), 123.CrossRefGoogle Scholar
Zarei, M., Chandran, S., Compston, A., & Hodges, J. (2003). Cognitive presentation of multiple sclerosis: Evidence for a cortical variant. Journal of Neurology, Neurosurgery and Psychiatry, 74(7), 872–7.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×